Figure 3 from Multiplexed P21/MCM-2 Detection Predicts Relapse and May Identify Tyrosine Kinase Inhibitor–Resistant Patients in Clear Cell Renal Cell Carcinoma

作者：Hazem Abdullah, In Hwa Um, Grant D. Stewart, Chang Wook Jeong, Cheol Kwak, Kyung Chul Moon, Alexander Laird, Eleni Frangou, Tim Eisen, Angela Meade, David J. Harrison · 年份：2026 · DOI：10.1158/2767-9764.32702079 · 研究领域：Renal cell carcinoma treatment、Multiple and Secondary Primary Cancers、Bladder and Urothelial Cancer Treatments

Validation of P21+/MCM2− cell content as a prognostic biomarker across high-risk LS SORCE and pan-risk LS Scottish cohorts. In both high-risk patients and the pan-risk cohort, a 2% threshold stratifies relapse risk, with higher proportions associated with favorable survival outcomes.